The Novavax COVID-19 vaccine program received a major boost when the U.S. government committed $1.6 billion in federal funding to accelerate clinical development and large scale manufacturing of NVX-CoV2373, the company’s lead vaccine candidate. The investment positions Novavax as one of the primary partners in Operation Warp Speed, the federal initiative aimed at delivering hundreds of millions of vaccine doses to the American public by 2021.
What Operation Warp Speed Means for NVX-CoV2373
Operation Warp Speed was designed to compress the traditional vaccine development timeline by funding multiple candidates simultaneously, increasing the probability that at least one safe and effective option would reach the public quickly. By including the Novavax COVID-19 vaccine alongside programs from Moderna and AstraZeneca, the government placed a strategic bet on multiple scientific approaches rather than a single solution.
For Novavax, the funding supports two critical objectives. First, it will finance the late stage clinical development of NVX-CoV2373, including a pivotal Phase III study enrolling up to 30,000 subjects. Second, it will fund the establishment of large scale manufacturing infrastructure capable of producing 100 million doses before the end of 2020.
“The pandemic has caused an unprecedented public health crisis, making it more important than ever that industry, government, and funding entities join forces to defeat the novel coronavirus together,” said Stanley C. Erck, President and CEO of Novavax. “We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis.”
The Science Behind the Novavax COVID-19 Vaccine
Novavax identified NVX-CoV2373 as its lead candidate in April 2020. The Novavax COVID-19 vaccine is built on the company’s proprietary nanoparticle technology and incorporates a Matrix-M adjuvant, an ingredient designed to enhance immune response and stimulate high levels of neutralizing antibodies against the virus.
In preclinical testing, NVX-CoV2373 demonstrated the ability to generate antibodies that block the virus’s spike protein from binding to cell receptors — a critical mechanism for effective protection. This spike protein blocking capability is considered one of the most promising indicators of vaccine efficacy in early stage research.
The company initiated a Phase I/II clinical trial in May 2020, with early safety and immunogenicity data expected by the end of July. The Phase II portion, evaluating immunity, safety, and disease reduction across a broader population, was set to begin immediately after those preliminary results were available.
Beyond the federal commitment, the Novavax COVID-19 vaccine development program also received up to $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support Phase I/II work, as well as an additional $60 million from the U.S. Department of Defense. Combined, these investments reflect broad institutional confidence in Novavax’s scientific platform.
From Clinical Trials to Regulatory Approval
No vaccine reaches the public without passing through a structured sequence of clinical trials. Each phase serves a distinct purpose. Phase I establishes safety and optimal dosing in a small group of volunteers. Phase II evaluates immune response and side effects across a larger population. Phase III confirms efficacy and monitors for adverse events at scale, typically in tens of thousands of participants across multiple sites.
The $1.6 billion agreement with the U.S. government covers the late stage clinical studies required to determine the safety and efficacy of NVX-CoV2373, and also allows for a follow-on arrangement to supply additional doses for national stockpiles. This funding further supports Novavax’s plans to file a licensure submission with the U.S. Food and Drug Administration.
U.S. Health and Human Services Secretary Alex Azar noted that adding the Novavax COVID-19 vaccine to Operation Warp Speed increases the overall probability of having a safe and effective option available to the public by the end of 2020.
Research networks with established Phase III infrastructure are essential to executing trials of this scale efficiently. FOMAT works with sponsors across the United States to support infectious disease and vaccine trials, providing access to diverse patient populations and experienced investigator teams capable of meeting the demands of large pivotal studies.
For More Information
- To read the original source, click here
- To learn more about our active studies, click here